157 related articles for article (PubMed ID: 16488554)
1. Augmentation of radiation response with the vascular targeting agent ZD6126.
Hoang T; Huang S; Armstrong E; Eickhoff JC; Harari PM
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1458-65. PubMed ID: 16488554
[TBL] [Abstract][Full Text] [Related]
2. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors.
Siemann DW; Rojiani AM
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):846-53. PubMed ID: 15936569
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model.
Raben D; Bianco C; Damiano V; Bianco R; Melisi D; Mignogna C; D'Armiento FP; Cionini L; Bianco AR; Tortora G; Ciardiello F; Bunn P
Mol Cancer Ther; 2004 Aug; 3(8):977-83. PubMed ID: 15299080
[TBL] [Abstract][Full Text] [Related]
4. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma.
Wachsberger PR; Burd R; Marero N; Daskalakis C; Ryan A; McCue P; Dicker AP
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):835-42. PubMed ID: 15701874
[TBL] [Abstract][Full Text] [Related]
5. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
[TBL] [Abstract][Full Text] [Related]
6. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.
Huang SM; Harari PM
Clin Cancer Res; 2000 Jun; 6(6):2166-74. PubMed ID: 10873065
[TBL] [Abstract][Full Text] [Related]
7. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice.
Goto H; Yano S; Zhang H; Matsumori Y; Ogawa H; Blakey DC; Sone S
Cancer Res; 2002 Jul; 62(13):3711-5. PubMed ID: 12097279
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.
Blakey DC; Westwood FR; Walker M; Hughes GD; Davis PD; Ashton SE; Ryan AJ
Clin Cancer Res; 2002 Jun; 8(6):1974-83. PubMed ID: 12060643
[TBL] [Abstract][Full Text] [Related]
9. ZD6126: a novel small molecule vascular targeting agent.
Blakey DC; Ashton SE; Westwood FR; Walker M; Ryan AJ
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1497-502. PubMed ID: 12459377
[TBL] [Abstract][Full Text] [Related]
10. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
Davis PD; Dougherty GJ; Blakey DC; Galbraith SM; Tozer GM; Holder AL; Naylor MA; Nolan J; Stratford MR; Chaplin DJ; Hill SA
Cancer Res; 2002 Dec; 62(24):7247-53. PubMed ID: 12499266
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
Goto H; Yano S; Matsumori Y; Ogawa H; Blakey DC; Sone S
Clin Cancer Res; 2004 Nov; 10(22):7671-6. PubMed ID: 15570000
[TBL] [Abstract][Full Text] [Related]
12. Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126.
Bozec A; Lassalle S; Gugenheim J; Fischel JL; Formento P; Hofman P; Milano G
Br J Cancer; 2006 Sep; 95(6):722-8. PubMed ID: 16940984
[TBL] [Abstract][Full Text] [Related]
13. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
14. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).
Huang SM; Li J; Armstrong EA; Harari PM
Cancer Res; 2002 Aug; 62(15):4300-6. PubMed ID: 12154033
[TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126.
Siemann DW; Rojiani AM
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1512-7. PubMed ID: 12459379
[TBL] [Abstract][Full Text] [Related]
16. Potential antagonism of tubulin-binding anticancer agents in combination therapies.
Taraboletti G; Micheletti G; Dossi R; Borsotti P; Martinelli M; Fiordaliso F; Ryan AJ; Giavazzi R
Clin Cancer Res; 2005 Apr; 11(7):2720-6. PubMed ID: 15814654
[TBL] [Abstract][Full Text] [Related]
17. Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel.
Martinelli M; Bonezzi K; Riccardi E; Kuhn E; Frapolli R; Zucchetti M; Ryan AJ; Taraboletti G; Giavazzi R
Br J Cancer; 2007 Oct; 97(7):888-94. PubMed ID: 17848949
[TBL] [Abstract][Full Text] [Related]
18. Combination of the antivascular agent ZD6126 with hypoxic cytotoxin treatment, with reference to the effect on quiescent tumor cells and the dependency on p53 status of tumor cells.
Masunaga S; Nagasawa H; Uto Y; Hori H; Ohnishi K; Takahashi A; Ohnishi T; Suzuki M; Nagata K; Kinashi Y; Ono K
Oncol Rep; 2005 Aug; 14(2):393-400. PubMed ID: 16012721
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.
Siemann DW; Rojiani AM
Int J Radiat Oncol Biol Phys; 2002 May; 53(1):164-71. PubMed ID: 12007956
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade.
Li J; Huang S; Armstrong EA; Fowler JF; Harari PM
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1477-85. PubMed ID: 16029810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]